RECRUITING

The Role of mGluR5 in CBT-I

Description

This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

Conditions

Major Depressive Disorder (MDD)
Talk to us

Related Conditions:

Major Depressive Disorder (MDD)

Study Overview

On this page

Study Details

Study overview

This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

Mechanistic Clinical Trial Evaluating the Role of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) in the Antidepressant Mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)

The Role of mGluR5 in CBT-I

Condition
Major Depressive Disorder (MDD)
Intervention / Treatment

-

Contacts and Locations

Stony Brook

Stony Brook University: Dept of Psychiatry, Stony Brook, New York, United States, 11794

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * capacity to provide informed consent,
  • * at least 18 years of age
  • * good physical health and absence of significant medical conditions,
  • * diagnosis of major depressive disorder (MDD) with current major depressive episode as per DSM-5 criteria
  • * Montgomery-Åsberg Depression Rating Scale (MADRS) score \> 29 (at least moderate depression),
  • * uniform range of sleep latencies up to 128 minutes.
  • * currently taking effective antidepressants,
  • * lifetime history of psychosis,
  • * drug or alcohol dependence in the last 6 months or abuse in the last 2 months
  • * unstable medical condition (i.e., condition not adequately stabilized for ≥ 3 months)
  • * nicotine use within 1 year
  • * currently on medication known to affect glutamate,
  • * sleep disorders, other than insomnia, such as sleep apnea,
  • * recent (within 1 year) regular night shift work (or rotating shift work) or recent (within 3 months) travel across more than one time zone, or plans for this work or travel during the study period,
  • * use of medication or substances that affect sleep, for example, ingestion of more \> 600 mg of caffeine per day,
  • * PET or MRI contraindications, including pregnancy or currently breastfeeding

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stony Brook University,

Study Record Dates

2030-06